GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adhera Therapeutics Inc (OTCPK:ATRX) » Definitions » Cash Flow from Investing

Adhera Therapeutics (Adhera Therapeutics) Cash Flow from Investing : $0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Adhera Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2023, Adhera Therapeutics spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Adhera Therapeutics gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2023.


Adhera Therapeutics Cash Flow from Investing Historical Data

The historical data trend for Adhera Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adhera Therapeutics Cash Flow from Investing Chart

Adhera Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 - - - -

Adhera Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Adhera Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Adhera Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2022 is calculated as:

Adhera Therapeutics's Cash Flow from Investing for the quarter that ended in Sep. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adhera Therapeutics  (OTCPK:ATRX) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Adhera Therapeutics's purchase of property, plant, equipment for the three months ended in Sep. 2023 was $0.00 Mil. It means Adhera Therapeutics spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Adhera Therapeutics's sale of property, plant, equipment for the three months ended in Sep. 2023 was $0.00 Mil. It means Adhera Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Adhera Therapeutics's purchase of business for the three months ended in Sep. 2023 was $0.00 Mil. It means Adhera Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Adhera Therapeutics's sale of business for the three months ended in Sep. 2023 was $0.00 Mil. It means Adhera Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Adhera Therapeutics's purchase of investment for the three months ended in Sep. 2023 was $0.00 Mil. It means Adhera Therapeutics spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Adhera Therapeutics's sale of investment for the three months ended in Sep. 2023 was $0.00 Mil. It means Adhera Therapeutics gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Adhera Therapeutics's net Intangibles purchase and sale for the three months ended in Sep. 2023 was $0.00 Mil. It means Adhera Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Adhera Therapeutics's cash from discontinued investing activities for the three months ended in Sep. 2023 was 0.00 Mil. It means Adhera Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Adhera Therapeutics's cash from other investing activities for the three months ended in Sep. 2023 was $0.00 Mil. It means Adhera Therapeutics paid $0.00 Mil for other investing activities.


Adhera Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Adhera Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Adhera Therapeutics (Adhera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8000 Innovation Parkway, Baton Rouge, LA, USA, 70820
Adhera Therapeutics Inc is an emerging specialty biotech company that is strategically evaluating its focus including a return to a drug discovery and development company.
Executives
Zahed Subhan director 8000 INNOVATION PARKWAY, BATON ROUGE LA 70820
Trond Kydd Waerness director 8000 INNOVATION PARKWAY, BAON ROUGE LA 70820
Rice Charles L Jr director C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113
Andrew Albert Kucharchuk director, officer: Chief Executive Officer 549 MILGATE PLACE, BATON ROUGE LA 70810
Rhonda L. Stanley officer: SVP Finance & Accounting 5001 SOUTH MIAMA BOULEVARD, SUITE 300, DURHAM NC 27703
Nancy R. Phelan director 812 MAPLEWOOD ROAD, WAYNE PA 19087
Robert Eric Teague officer: Chief Financial Officer C/O MARINA BIOTECH, INC., 4721 EMPEROR BOULEVARD, SUITE 350, DURHAM NC 27703
Uli Hacksell director 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Robert Jr. Moscato officer: CEO 400 PRATT STREET, SUITE 606, BALTIMORE MD 21202
Timothy Boris director 805 AEROVISTA PLACE, SUITE 205, SAN LUIS OBISPO CA 93401
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Peter D. Weinstein officer: Chief Legal Officer C.O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Amit B. Shah officer: Chief Financial Officer 10 AGUILA, ALISO VIEJO CA 92656
Erik C. Emerson officer: Chief Commercial Officer 2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102
Mihir Munsif officer: Chief Operating Officer 21102 BRIARWOOD LANE, TRABUCO CANYON CA 92679

Adhera Therapeutics (Adhera Therapeutics) Headlines

From GuruFocus

Marina Biotech Appoints Eric Teague as Chief Financial Officer

By Marketwired Marketwired 09-24-2018

MDRNA Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-12-2009